Increasing evidence indicates that inflammation promotes thrombosis via a VWF (von
Willebrand factor)-mediated mechanism. VWF plays an essential role in maintaining the …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the cause of
coronavirus infectious disease (COVID‐19) and has rapidly spread worldwide, causing …

Although thrombosis frequently occurs in infectious diseases, the coagulopathy associated
with COVID-19 has unique characteristics. Compared with bacterial sepsis, COVID-19 …

ADAMTS13, a metalloproteinase, specifically cleaves unusually large multimers of von
Willebrand factor (VWF), newly released from vascular endothelial cells. The ratio of …

Background COVID-19 is accompanied by a hypercoagulable state and characterized by
microvascular and macrovascular thrombotic complications. In plasma samples from …

Objective: This study determined if an accessible, serologic indicator of vascular disease
activity, the von Willebrand factor antigen (vWF: Ag), was useful to assess disease activity in …

Background Antithrombin is considered as one of the accused markers for the development
of thrombosis in patients with COVID-19. Because plasma levels of antithrombin vary in …

Galectin-3 is a beta-galactoside-binding lectin involved in inflammation and lung fibrosis
and postulated to enhance thrombosis. In COVID-19, it is considered to be a prognostic …

Immuno-thrombosis of COVID-19 results in the activation of platelets and coagulopathy.
Antiplatelet therapy has been widely used in COVID-19 patients to prevent thrombotic …

Abstract Background Coagulation factor VIII (FVIII) and von Willebrand factor (VWF) circulate
as a noncovalent complex, but each has its distinct functions. Binding of FVIII to VWF results …